Main Menu
Menu

Resources

Publish Date
Resources
Issue Briefs
Congress Should Pass PERA to Fix What the Supreme Court Unintentionally Broke
Resources
Public Comments
C4IP Comments RE: The Section 301 Investigation of Vietnam’s Acts, Policies, and Practices Related to Intellectual Property Protection (USTR-2026-0364)
Resources
Public Comments
C4IP Comments RE: The Section 301 Investigation of Brazil’s Acts, Policies, and Practices Related to Intellectual Property Protection (USTR-2026-0331)
Resources
Letters
C4IP Letter to House Judiciary Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet RE: Hearing on IP and the Internet
Resources
Letters
C4IP Letter to Senate Finance Committee RE: Nomination of Peter-Anthony Pappas to the U.S. International Trade Commission
Resources
Letters
C4IP Letter to Senate HELP Committee RE: Consideration of Medication Affordability and Patent Integrity Act
C4IPResources
Letters
C4IP Letter to Senate HELP Committee RE: Medication Affordability and Patent Integrity Act Markup
Resources
External ResourcesReports
Idea Factories: How Intellectual Property Sustains and Cultivates Technology Ecosystems
Resources
Letters
C4IP Letter to House Judiciary Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet RE: Hearing on Medicines and IP
Resources
Issue Briefs
Myths vs. Facts: Terminal Disclaimers
Resources
Issue Briefs
Myths vs. Facts: The Eliminating Thickets to Increase Competition (ETHIC) Act
Resources
Letters
Letter to House Committee on Ways & Means RE: USTRx Act
Resources:

Resources:

C4IP Letter to Senate HELP Committee RE: Hearing on The Medication Affordability and Patent Integrity Act,

09/25/2024
Resources:

Resources:

C4IP Letter to Senate Judiciary Committee RE: PERA,

09/24/2024
Resources:

Resources:

C4IP Letter to Senate Judiciary Committee RE: PERA, PREVAIL Act, and IDEA Act,

09/18/2024
Resources:

Resources:

C4IP Letter to Senate Judiciary Committee RE: IDEA Act,

09/17/2024
Resources:

Resources:

C4IP Comments RE: 2024 Guidance Update on Patent Subject Matter Eligibility, Including on Artificial Intelligence (PTO-P-2024-0026),

09/16/2024
Resources:

Resources:

Overview of the USPTO Drug Exclusivity Report,

09/12/2024
Resources:

Resources:

C4IP Letter to Senate HELP Committee RE: The Medication Affordability and Patent Integrity Act,

08/26/2024
Resources:

Resources:

C4IP Comments RE: The Impact of the Proliferation of Artificial Intelligence on Prior Art, the Knowledge of a Person Having Ordinary Skill in the Art, and Determinations of Patentability Made in View of the Foregoing (PTO-P-2023-0044),

07/29/2024
Resources:

Resources:

C4IP Letter to House Judiciary Committee RE: IP Litigation and the U.S. International Trade Commission,

07/22/2024
Resources:

Resources:

C4IP Comments RE: Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (PTO-P-2024-0003),

07/09/2024
Resources:

Resources:

C4IP Comments RE: Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (PTO-P-2023-0048),

06/18/2024
Resources:

Resources:

C4IP Comments RE: Rules Governing Director Review of Patent Trial and Appeal Board Decisions (PTO-P-2024-0014),

06/17/2024
Scroll to Top